CRIS Current Research Information System

CURTI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.324
EU - Europa 3.901
AS - Asia 1.952
AF - Africa 262
Continente sconosciuto - Info sul continente non disponibili 19
SA - Sud America 15
OC - Oceania 6
Totale 11.479
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.288
GB - Regno Unito 1.038
SE - Svezia 809
IT - Italia 659
CN - Cina 643
SG - Singapore 543
DE - Germania 452
VN - Vietnam 314
IN - India 238
IE - Irlanda 170
UA - Ucraina 137
RU - Federazione Russa 123
FR - Francia 112
TG - Togo 103
ZA - Sudafrica 71
JO - Giordania 70
BG - Bulgaria 68
CH - Svizzera 58
EE - Estonia 58
GR - Grecia 58
FI - Finlandia 46
CI - Costa d'Avorio 40
BE - Belgio 38
CA - Canada 36
NG - Nigeria 30
IR - Iran 24
TR - Turchia 22
ID - Indonesia 21
EU - Europa 18
JP - Giappone 17
KR - Corea 16
NL - Olanda 14
SC - Seychelles 13
ES - Italia 10
AT - Austria 9
PH - Filippine 9
PL - Polonia 9
BR - Brasile 8
LB - Libano 7
HK - Hong Kong 6
CL - Cile 5
LT - Lituania 5
RO - Romania 5
AU - Australia 4
CZ - Repubblica Ceca 4
HR - Croazia 4
QA - Qatar 4
BD - Bangladesh 3
MA - Marocco 3
MY - Malesia 3
NO - Norvegia 3
RS - Serbia 3
TH - Thailandia 3
TW - Taiwan 3
HU - Ungheria 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
EG - Egitto 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MK - Macedonia 1
PE - Perù 1
UG - Uganda 1
Totale 11.479
Salva come PNG Salva come JPEG
Città #
Southend 951
Chandler 644
Fairfield 599
Singapore 483
Ashburn 393
Woodbridge 301
Wilmington 273
Ann Arbor 270
Seattle 250
Houston 245
Santa Clara 243
Princeton 204
Cambridge 203
Dong Ket 202
Dublin 170
Boardman 125
Bologna 121
Lomé 103
Westminster 86
Nanjing 79
Beijing 75
Padova 72
Amman 70
Sofia 68
Jacksonville 62
New York 61
Bern 51
Berlin 49
Bremen 47
Jinan 45
Helsinki 43
San Diego 41
Abidjan 40
Hyderabad 39
Brussels 38
Turin 38
Milan 37
Shenyang 37
Medford 32
Saint Petersburg 32
Tianjin 31
Abeokuta 30
Florence 27
Zhengzhou 27
Nanchang 26
Hebei 24
Redmond 23
Jakarta 21
Rome 20
Frankfurt am Main 19
Redwood City 19
Istanbul 17
Jiaxing 17
Los Angeles 17
Changsha 15
Guangzhou 15
Mülheim 15
Norwalk 15
Des Moines 14
Toronto 14
Grafing 13
Mahé 13
Shanghai 13
Tokyo 13
Falls Church 12
Lanzhou 12
Washington 12
Hangzhou 11
Dearborn 10
Andover 9
Athens 9
Bühl 9
Davao City 9
Dehradun 9
Haikou 9
London 9
Ningbo 9
North York 9
Wuhan 9
Benevento 8
Fremont 8
Fuzhou 8
Leawood 8
Olalla 8
Foshan 7
Kunming 7
Ottawa 7
Phoenix 7
Pune 7
Taiyuan 7
Verona 7
Zanjan 7
San Francisco 6
São Paulo 6
Vienna 6
Boydton 5
Chicago 5
Gradara 5
Irvine 5
Madrid 5
Totale 7.666
Salva come PNG Salva come JPEG
Nome #
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 228
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 218
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 194
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 190
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 190
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 180
A case report of acute myeloid leukemia and neurofibromatosis 1 178
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 163
ATP release from chemotherapy-treated dying leukemia cells Elicits an immune suppressive effect by increasing regulatory T cells and Tolerogenic dendritic cells 157
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 155
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 155
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 154
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 152
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 150
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 147
Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease 145
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 144
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 143
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 143
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 141
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 138
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 136
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 135
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 134
Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation 134
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 132
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia 132
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 132
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 131
Immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: Time for a biology-driven approach 131
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 130
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 129
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 128
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. 127
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 127
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 127
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 126
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 125
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 124
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 124
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 124
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 123
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response 123
The more, the better: "Do the right thing" for natural killer immunotherapy in acute myeloid leukemia 123
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 122
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 122
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 122
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. 120
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 120
Dendritic cell differentiation. 119
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 119
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 118
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 117
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy 115
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 114
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 113
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 111
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. 109
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 109
null 107
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 107
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 106
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 106
Immune characterization in Narcolepsy Type 1. 104
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 104
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 104
Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells 104
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 103
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 102
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 101
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 98
Corrigendum: Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells (Front. Oncol, (2020), 10, (1225), 10.3389/fonc.2020.01225) 98
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 96
null 93
More ADO about IDO: GVHD. 92
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 88
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 87
A phase I study of Tipifarnib and Bortezomib in the treatment of poor risk adult acute myeloid leukemia (AML) 87
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 80
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 78
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 77
FLUDARABINE, CYTARABINE, IDARUBICIN AND ETOPOSIDE (FLAIE) SCHEDULE IS SAFE AND ACTIVE FOR YOUNG PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF A MULTICENTRIC PHASE III ITALIAN STUDY 76
Progetto “Scalo Internazionale Migranti” 76
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 73
Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade 72
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 71
The P2X7 receptor: a new player in IL-1 processing and release 70
The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia 70
Emerging bone marrow microenvironment‐driven mechanisms of drug resistance in acute myeloid leukemia: Tangle or chance? 69
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 62
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 61
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 60
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 59
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 57
Granulocyte colony-stimulating factor promotes the generation of regulatory DCs through induction of IL-10 and IFN-alfa. 56
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 54
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 54
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 53
A screening of antineoplastic drugs for acute myeloid leukemia reveals contrasting immunogenic effects of etoposide and fludarabine 53
Release of IFNg by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells 52
Totale 11.492
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.516
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.516
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.392 0 0 0 0 0 0 284 302 362 173 125 146
2020/20211.319 241 71 24 51 68 82 34 108 135 87 42 376
2021/20222.233 153 67 131 226 193 128 45 168 127 191 415 389
2022/20232.604 332 406 125 322 189 203 84 149 423 50 171 150
2023/2024770 49 114 43 101 58 170 40 36 27 38 69 25
2024/20251.538 153 377 228 207 418 153 2 0 0 0 0 0
Totale 11.786